-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Compugen (NASDAQ:CGEN) Cut to "Sell" at StockNews.com
Compugen (NASDAQ:CGEN) Cut to "Sell" at StockNews.com
StockNews.com downgraded shares of Compugen (NASDAQ:CGEN – Get Rating) from a hold rating to a sell rating in a report published on Friday.
Several other research firms have also recently weighed in on CGEN. Truist Financial cut their price target on shares of Compugen from $14.00 to $4.00 and set a buy rating on the stock in a report on Tuesday, August 23rd. Oppenheimer decreased their target price on Compugen from $14.00 to $12.00 and set an outperform rating for the company in a research report on Monday, August 8th. Jefferies Financial Group downgraded shares of Compugen from a buy rating to a hold rating and set a $2.00 price objective for the company. in a report on Friday, August 5th. Finally, JMP Securities reduced their target price on shares of Compugen from $8.00 to $4.00 and set a market outperform rating for the company in a research report on Monday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $6.20.
Get Compugen alerts:Compugen Price Performance
Shares of Compugen stock opened at $1.04 on Friday. Compugen has a one year low of $0.99 and a one year high of $7.48. The stock's 50-day moving average is $1.57 and its 200 day moving average is $2.13. The firm has a market cap of $90.09 million, a price-to-earnings ratio of -2.67 and a beta of 2.15.
Compugen (NASDAQ:CGEN – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. During the same period in the prior year, the business earned ($0.11) EPS. On average, sell-side analysts expect that Compugen will post -0.43 EPS for the current fiscal year.Institutional Trading of Compugen
Several institutional investors and hedge funds have recently bought and sold shares of CGEN. Raymond James & Associates boosted its stake in Compugen by 5.4% during the fourth quarter. Raymond James & Associates now owns 213,510 shares of the biotechnology company's stock valued at $918,000 after buying an additional 11,015 shares during the period. BNP Paribas Arbitrage SA bought a new stake in shares of Compugen during the 4th quarter valued at about $1,760,000. Virtus ETF Advisers LLC grew its holdings in shares of Compugen by 60.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 40,161 shares of the biotechnology company's stock worth $173,000 after purchasing an additional 15,182 shares in the last quarter. PDT Partners LLC grew its stake in Compugen by 55.9% in the 4th quarter. PDT Partners LLC now owns 220,083 shares of the biotechnology company's stock worth $946,000 after buying an additional 78,883 shares in the last quarter. Finally, Antonetti Capital Management LLC increased its holdings in shares of Compugen by 7.6% in the 4th quarter. Antonetti Capital Management LLC now owns 247,900 shares of the biotechnology company's stock worth $1,066,000 after buying an additional 17,582 shares during the last quarter.
Compugen Company Profile
(Get Rating)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
See Also
- Get a free copy of the StockNews.com research report on Compugen (CGEN)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com downgraded shares of Compugen (NASDAQ:CGEN – Get Rating) from a hold rating to a sell rating in a report published on Friday.
斯托克新闻网在周五发布的一份报告中将纳斯达克股票评级从持有下调至卖出。
Several other research firms have also recently weighed in on CGEN. Truist Financial cut their price target on shares of Compugen from $14.00 to $4.00 and set a buy rating on the stock in a report on Tuesday, August 23rd. Oppenheimer decreased their target price on Compugen from $14.00 to $12.00 and set an outperform rating for the company in a research report on Monday, August 8th. Jefferies Financial Group downgraded shares of Compugen from a buy rating to a hold rating and set a $2.00 price objective for the company. in a report on Friday, August 5th. Finally, JMP Securities reduced their target price on shares of Compugen from $8.00 to $4.00 and set a market outperform rating for the company in a research report on Monday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $6.20.
其他几家研究公司最近也参与了CGEN的研究。Truist Financial在8月23日(星期二)的一份报告中将Compugen的股票目标价从14.00美元下调至4.00美元,并对该股设定了买入评级。奥本海默在8月8日周一的一份研究报告中将其对Compugen的目标价从14.00美元下调至12.00美元,并为该公司设定了表现优于大盘的评级。杰富瑞金融集团将Compugen的股票评级从买入下调至持有,并为该公司设定了2.00美元的目标价。在8月5日星期五的一份报告中。最后,JMP证券在8月8日星期一的一份研究报告中将Compugen的股票目标价从8.00美元下调至4.00美元,并为该公司设定了表现优于市场的评级。一名投资分析师对该股的评级为卖出,一名分析师发布了持有评级,四名分析师对该公司给予了买入评级。根据MarketBeat的数据,该公司目前的平均评级为中等买入,共识目标价为6.20美元。
Compugen Price Performance
Compugen价格表现
Shares of Compugen stock opened at $1.04 on Friday. Compugen has a one year low of $0.99 and a one year high of $7.48. The stock's 50-day moving average is $1.57 and its 200 day moving average is $2.13. The firm has a market cap of $90.09 million, a price-to-earnings ratio of -2.67 and a beta of 2.15.
上周五,Compugen的股票开盘报1.04美元。Compugen的一年低点为0.99美元,一年高位为7.48美元。该股的50日移动均线切入位在1.57美元,200日移动均线切入位在2.13美元。该公司市值为9,009万美元,市盈率为-2.67倍,贝塔系数为2.15。
Institutional Trading of Compugen
Compugen的机构性交易
Several institutional investors and hedge funds have recently bought and sold shares of CGEN. Raymond James & Associates boosted its stake in Compugen by 5.4% during the fourth quarter. Raymond James & Associates now owns 213,510 shares of the biotechnology company's stock valued at $918,000 after buying an additional 11,015 shares during the period. BNP Paribas Arbitrage SA bought a new stake in shares of Compugen during the 4th quarter valued at about $1,760,000. Virtus ETF Advisers LLC grew its holdings in shares of Compugen by 60.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 40,161 shares of the biotechnology company's stock worth $173,000 after purchasing an additional 15,182 shares in the last quarter. PDT Partners LLC grew its stake in Compugen by 55.9% in the 4th quarter. PDT Partners LLC now owns 220,083 shares of the biotechnology company's stock worth $946,000 after buying an additional 78,883 shares in the last quarter. Finally, Antonetti Capital Management LLC increased its holdings in shares of Compugen by 7.6% in the 4th quarter. Antonetti Capital Management LLC now owns 247,900 shares of the biotechnology company's stock worth $1,066,000 after buying an additional 17,582 shares during the last quarter.
几家机构投资者和对冲基金最近买卖了CGEN的股票。Raymond James&Associates在第四季度将其在Compugen的持股增加了5.4%。Raymond James&Associates在此期间又购买了11,015股,现在拥有213,510股这家生物技术公司的股票,价值918,000美元。法国巴黎银行套利公司在第四季度购买了Compugen价值约1,76万美元的新股。Virtus ETF Advisers LLC在第四季度增持了60.8%的Compugen股票。Virtus ETF Advisers LLC现在拥有40,161股这家生物技术公司的股票,价值173,000美元,上个季度又购买了15,182股。PDT Partners LLC在第四季度增持了55.9%的Compugen股份。PDT Partners LLC现在拥有220,083股这家生物技术公司的股票,价值946,000美元,上个季度又购买了78,883股。最后,Antonetti Capital Management LLC在第四季度增持了7.6%的Compugen股票。Antonetti Capital Management LLC现在拥有247,900股这家生物技术公司的股票,价值1066,000美元,在上个季度又购买了17,582股。
Compugen Company Profile
Compugen公司简介
(Get Rating)
(获取评级)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Compugen有限公司是一家临床阶段的治疗发现和开发公司,在以色列、美国和欧洲研究、开发和销售候选治疗和产品。该公司的免疫肿瘤学产品线包括COM701,一种用于治疗实体肿瘤的抗PVRIG抗体,处于第一阶段临床研究;COM902,一种针对TIGIT的治疗性抗体,正处于对晚期癌症患者的单一疗法的第一阶段临床研究;Bapotulimab,一种针对ILDR2的治疗性抗体,正处于实体肿瘤患者的第一阶段临床研究;以及AZD2936,一种新型的抗TIGIT/PD-1双特异性抗体,正处于针对晚期或转移性非小细胞肺癌患者的I/II临床研究。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Compugen (CGEN)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- 免费获取StockNews.com关于Compugen的研究报告(CGEN)
- 电子艺界能扭转电子游戏市场的低迷吗?
- 美元将军是美国小池塘里的大鱼。
- 以下是CPI报告将决定市场底部的原因
- MarketBeat:回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
接受Compugen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Compugen和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧